These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24860905)

  • 1. New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps.
    Prescrire Int; 2014 Apr; 23(148):107-10. PubMed ID: 24860905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
    Prescrire Int; 2015 Apr; 24(159):107-10. PubMed ID: 25941710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
    Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs and indications in 2010: inadequate assessment; patients at risk.
    Prescrire Int; 2011 Apr; 20(115):105-7, 109-10. PubMed ID: 21648217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital readmission for adverse drug reactions.
    Prescrire Int; 2015 Feb; 24(157):46. PubMed ID: 25802920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere.
    Prescrire Int; 2012 Apr; 21(126):106-10. PubMed ID: 22515141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards better patient care: drugs to avoid in 2014.
    Prescrire Int; 2014 Jun; 23(150):161-5. PubMed ID: 25121155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug packaging in 2013: small changes would reap big benefits.
    Prescrire Int; 2014 May; 23(149):136-8. PubMed ID: 24926522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced acute pancreatitis.
    Prescrire Int; 2014 Apr; 23(148):101. PubMed ID: 24860896
    [No Abstract]   [Full Text] [Related]  

  • 16. Faster drug approval: challenges for safety.
    Preziosi P
    Expert Opin Drug Saf; 2016 Sep; 15(9):1205-18. PubMed ID: 27308948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of drugs withdrawn from the market.
    Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
    Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of labeling decisions regarding therapeutic indications during new drug application reviews in Japan.
    Yokota M; Kusama M; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2011 Sep; 90(3):432-41. PubMed ID: 21814198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology for the geriatric surgical patient.
    Then J; Tisherman SA
    Surg Clin North Am; 2015 Feb; 95(1):139-47. PubMed ID: 25459548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.